Tag - ONTX

Onconova Logo

HCW cuts Onconova Therapeutics to neutral; removes PT

H.C. Wainwright downgraded Onconova Therapeutics (NASDAQ:ONTX) to “neutral” from “buy” without a price target after the company’s Phase 3 INSPIRE trial with rigosertib in high-risk myelodysplastic syndromesfailed on...

Onconova Logo

Maxim ups Onconova Therapeutics PT to $3 from $1.25

Maxim Group raised its price target for Onconova Therapeutics (NASDAQ:ONTX) to $3 from $1.25 after the company announced that the required number of survival events for the pivotal Phase 3 INSPIRE study of IV rigosertib...

Onconova Logo

Maxim ups Onconova Therapeutics to buy; PT $1.25

Maxim Group upgraded Onconova Therapeutics (NASDAQ:ONTX) to “buy” from “hold” with a new price target of $1.25, citing a strengthened balance sheet, and a sufficient cash runway into the third quarter of 2021, well past...

Onconova Logo

Noble starts Onconova Therapeutics at OP; PT $12

Noble Financial launched coverage of Onconova Therapeutics (NASDAQ:ONTX) with an “outperform” rating and $12 price target. The stock was quoted at $2.62 at midday on July 25. Onconova is currently focused on completing...

Sign up for the BioTuesdays weekly newsletter

Get the latest news on the healthcare industry’s corporate and clinical developments, executive moves, and market updates. Every Tuesday, in your inbox.